MiRNA-218 inhibits cell proliferation, migration and invasion by targeting Runt-related transcription factor 2 (Runx2) in human osteosarcoma cells

Qiang Guo a, Junan Ma b, Jing Wu c, * a Department of Thoracic Surgery, Jinan Fifth People’s Hospital, No. 24297, Jingshi Road, Huaiyin District, Jinan City, Shandong, 250022, China b Department of Orthopedics, Chengwu County People’s Hospital Affiliated to First Medical University of Shandong, No. 66, BoLe Street, Chengwu County, Heze City, Shandong, 274200, China c Department of Orthopedics, The Affiliated Huai’an Hospital of Xuzhou Medical University, The Second People’s Hospital of Huai’an, Huai’an, Jiangsu Province, 223001, China

1. Introduction

Osteosarcoma (OS) is a malignant bone tumor most frequently diagnosed in adolescents and young adults [1]. Patients with OS often complain of pain and fracture-related symptoms. OS is responsible for 20% of all primary bone cancers in patients. Each year, the incidence of OS varies by population, ranging from 4.6 per million whites to 6.8 per million blacks, and there is a gender disparity [2]. Surgery and chemotherapy are the primary treatments for OS. Despite advancements in management, current therapies have not been shown to affect recurrent or metastatic OS significantly. The 5-year survival rate for metastatic OS patients is reported to be low, ranging between 20% and 30% [3,4]. OS has been a global health concern, and a novel treatment is urgently needed.

Numerous studies have concentrated on the discovery of novel biomarkers for prognosis prediction and the development of targeted therapies. A recent study demonstrated that osteopontin, which is expressed in bone tissues, is involved in OS growth and metastasis and has been proposed as a therapeutic target for OS [5]. Inactivation of the tumor suppressor genes p53, pRB, and RecQL helicase has been reported in OS, and these genes have been proposed as potential therapeutic targets [6,7]. Runt-related transcription factor 2 (Runx2), a member of the RUNX transcription factor family, is also known as CBFa-1. It is a heterodimeric complex
that can bind DNA as a subunit and is involved in osteoblast differ-
entiation and skeletal morphogenesis [8]. Runx2 is required for
early osteoblast differentiation and serves as the master gene for
bone formation [9]. Runx2 was identified as a critical molecular
marker in the etiology of osteosarcoma by Nathan et al. [10]; Lucero
et al. demonstrated that Runx2 promoted human osteosarcoma cell
proliferation [11]; and Del et al. demonstrated that WWOX inhibi-
ted osteosarcoma metastasis by decreasing Runx2 expression [12].
Runx2 overexpression in the osteoblast lineage of transgenic mice
inhibits osteoblast maturation, increases bone resorption, and re-
sults in osteopenia with multiple fractures [11]. These studies
established that osteoblasts can circumvent Runx2-mediated strict
growth regulation and form tumor-like osteoblasts.

MicroRNAs (miRNAs) are a class of small non-coding RNAs that
play a critical role in gene expression regulation. By post-
transcriptionally regulating target genes, miRNA deregulation is
play a critical role in gene expression regulation. By post-
growth regulation and form tumor-like osteoblasts.

MicroRNAs (miRNAs) are a class of small non-coding RNAs that
play a critical role in gene expression regulation. By post-
transcriptionally regulating target genes, miRNA deregulation is
play a critical role in gene expression regulation. By post-
growth regulation and form tumor-like osteoblasts.

The human OS cell lines (Saos-2, 143B, U2OS, and MG-63) and
human osteoblast cell line hFOB1 were used. hFOB1 cells were
grown in D-MEM/F-12 medium (GIBCO, USA), Saos-2 cells in Mc-
Coy's 5a medium (GIBCO, USA), 143B cells in Eagle's minimum
essential medium (Corning, USA), and U2OS and MG-63 cells in
RPMI 1640 medium (GIBCO, USA). All cell lines were cultured in the
same manner as described in the Cell Bank of the Chinese Academy of
Sciences (https://www.cellbank.org.cn/index.php).

2. Methods and materials
2.1. Tissue sample collection
Between February 2012 and January 2019, 82 OS patients (41
males and 41 females) undergoing surgery at Huai’an Second
People’s Hospital Second had their paired tumor and adjacent normal tis-
sues harvested after providing informed consent. Patients between
the ages of 15 and 24 years were included, but those who had
received radiotherapy or chemotherapy prior to surgery were
excluded. Table 1 summarizes the basic characteristics of the pa-
tients included.

2.2. Cell culture
The human OS cell lines (Saos-2, 143B, U2OS, and MG-63) and
human osteoblast cell line hFOB1 were used. hFOB1 cells were
grown in D-MEM/F-12 medium (GIBCO, USA), Saos-2 cells in Mc-
Coy’s 5a medium (GIBCO, USA), 143B cells in Eagle’s minimum
essential medium (Corning, USA), and U2OS and MG-63 cells in
RPMI 1640 medium (GIBCO, USA). All cell lines were cultured in the
same manner as described in the Cell Bank of the Chinese Academy of
Sciences (https://www.cellbank.org.cn/index.php).

2.3. RT (reverse transcription)-PCR analysis
Total RNA was extracted from tissue and cell samples using the
TRIzol method (Invitrogen, USA). TaqMan miRNA reverse tran-
scription kit (Thermo Fisher Scientific, USA) was used to reverse
transcribe the specific cDNA for miRNAs according to the manu-
facturer’s instructions. MiRNA-218 expression was measured in
comparison to U6 using PCR. The expression of Runx2 relative to
GAPDH was achieved with the primers of Forward: 5’-TGAC-
CAGCTTTACCCCTTCTCT-3’, Reverse: 5’-CTGAAAGCATGAAATGCG-3’.
There were four replications for each assay.

2.4. Transfection
The miRNA-218 mimics (5’-UGUGACGUACUAUGAAUCU-3’),
siRNA (5’-AUGGUGCCUGUGAAUCUACCA-3’), and the control
sequence (5’-GUGGAGAUAUGCAGCCACUGA-3’) inserted plasmids
were obtained from Shanghai GenePharma Co., China. The miRNA-
218-overexpression and miRNA-Ctrl U2OS cells were achieved by
lipofection transfection (Invitrogen, USA) after transfection with
40 nM miRNA-218 mimics or its control. The adenovirus expressing
Runx2 vector and controls were constructed and transfected as per
the previous description [21]. After transfection for 24 h, the ex-
pressions of miRNA-218 and Runx2 were detected by RT-qPCR
analysis.

2.5. Colony formation and CCK-8 assay
After transfection, cells were collected and transferred to the
fresh culture media for further analysis. When the cells grew to 50%
confluence, cells (600 cells/well) were plated in a 6-well plate and
cultured for two weeks. Following incubated with 0.1% crystal vi-
олет для 10 min, the photos of colony formation were taken and
analyzed.

For Cell Counting Kit-8 assay, cells were plated on the 96 well
plate and cultured. Cells were incubated with CCK-8 solution (100
μL/well, Beyotime, China) for 12, 24, 48, 72 h, and the optical
density (OD) value of cultures was determined at 480 nm under a
microplate spectrophotometer (Thermo, Waltham, MA, USA).

2.6. Cell migration and invasion assay
For wound-healing, cells were seeded in the 6-well plate and
cultured for 8–24 h. When cells grew to 90% confluence, each well
with cultured cells was scratched by a 200 μl pipette tip followed by
48 h culture. The photos of cultured cells were captured at 0, and
48 h in the same position and the area of wound-healing was
analyzed.

Transwell assay was applied to evaluate the changes in cell
metastasis ability. Cells were seeded in the Matrigel-coated
Transwell or normal Transwell plate (Costar, USA) of the upper
chamber at 5 × 10^4 cells/well. The bottom of the Transwell plate
was added with 400 μl DMEM with 10% PBS. Following 24 h in-
cubation, cells on the upper surface of the Transwell filter mem-
brane were wiped off, and the membrane and lower chamber
cultures were stained with 0.1% crystal violet. After dried, the
staining cells were observed at three random fields under a
microscope.

2.7. Prediction of the target interaction between miRNA-218 and
Runx2
The target interaction between miRNA-218 and Runx2 was
predicted with the application of the TargetScan online tool and
determined by the dual-luciferase reporter assay (Abcam, Cam-
bridge, UK), as the manufacturer described. Briefly, the wide-type
or mutant 3’-UTR sequences of Runx2 were cloned to the lucif-
erase reporter vector. The recombinant plasmid, miRNA-218
mimics, and miRNA-218-ctrl vector was co-transfected to U2OS
cells. Then, the transfected cells were maintained for 48 h, and
the luciferase signals were evaluated by fluorescence microplate.
2.8. Western blotting

The indicated cells were lysed using RIPA lysis reagent (Sigma, USA). The concentration of the supernatant was quantified by BCA Protein Assay Kit (Thermo Fisher Scientific, USA). Then the protein was separated by 10% sodium dodecyl polyacrylamide gels and transferred onto PVDF membrane (Millipore, USA). After blocking with 5% nonfat milk for 1h, the membrane was incubated with primary antibody against Runx2 (Abcam, ab236639, 1:1000) and β-actin (Abcam, ab5694, 1:1000) at 4°C overnight, followed by incubated with HRP-linked secondary antibody (Abcam, ab7090, 1:1000) for 1h. The protein bands were quantified by ImageJ software and β-actin functioned as the internal control.

2.9. Statistical analysis

The data were displayed as mean ± standard deviation (SD) and analyzed by SPSS software. The multi-group comparison was analyzed by the one-way ANOVA method followed by Tukey’s analysis. Student’s t-test was used to analyze the difference between the two groups. Differences with a p-value < 0.05 were considered as statistically significant.

---

**Table 1**
The basic information of osteosarcoma patients included in our study.

| Characteristics         | n   | miRNA-218               | P   |
|-------------------------|-----|-------------------------|-----|
|                         |     | Low         | High       |
| Age (years)             |     |             |             |
| <20                     | 29  | 13          | 16          |
| ≥20                     | 53  | 28          | 25          |
| Gender                  |     |             |             |
| Male                    | 41  | 20          | 21          |
| Female                  | 41  | 18          | 23          |
| Tumor size (cm)         |     |             |             |
| <8                      | 36  | 20          | 16          |
| ≥8                      | 46  | 24          | 22          |
| Tumor stage             |     |             |             |
| I                       | 23  | 18          | 5           |
| II/III                  | 59  | 31          | 28          |
| Metastasis              |     |             |             |
| Absent                  | 57  | 27          | 30          |
| Present                 | 25  | 19          | 6           |

NS: no significant difference.

---

Fig. 1. The expression of miRNA-218 and Runx2 in osteosarcoma tissues and cell lines. (A) The expression of miRNA-218 was detected in 20 paired tumor tissues and normal tissues. The expression of miRNA-218 was significantly declined in osteosarcoma tissues, compared with controls. The expression of miRNA-218 (B) and Runx2 (C) in hFOB1.19, Saos-2, U-2OS, MG-63 and 143B cell lines. MiRNA-218 expression was significantly lower in osteosarcoma cell lines. *P < 0.01, compared with normal tissues. **P < 0.05. ***P < 0.01 and ****P < 0.001, compared with hFOB1.19 cells.
Fig. 2. The inhibitive effect of miRNA-218 overexpression on the proliferation, colony formation, migration and invasion of U-2OS cells. (A) The miRNA-218 overexpression cells were achieved by transfection with miRNA mimics. The positive transfection was detected by qRT-PCR analysis. The expression of miRNA-218 was significantly elevated in cells transfected with miRNA-218 mimics. (B) The effect of miRNA-218 overexpression on cell proliferation was detected by CCK-8 analysis. miRNA-218 overexpression significantly inhibited cell proliferation, compared with controls. (C) The colony formation of miRNA-218 overexpression cells was analyzed. The number of colonies was the lowest in cells transfected with miRNA mimics. (D) The changes of migration ability after miRNA-218 overexpression were observed by cell scratch assay. miRNA-218 overexpression obviously suppressed the cell wound-healing ability. The effect of the overexpression of miRNA-218 on cell invasion (E and F) and migration (E and G) was measured by Transwell assay. miRNA-218 overexpression remarkably inhibited cell invasion and migration. *\(p < 0.01\) compared with miRNA-ctrl group; **\(p < 0.01\) compared with blank group; ***\(p < 0.01\) compared with indicated group; NS: no significant difference.
3. Results

3.1. MiRNA-218 was poorly expressed, and Runx2 was highly expressed in OS tissues and cell lines

The expressions of miRNA-218 and Runx2 were investigated using RT-qPCR. Compared with normal controls, miRNA-218 expression was significantly down-regulated in OS tumor tissues ($P < 0.01$, Fig. 1A). The human OS cell lines (Saos-2, 143B, U2OS, and MG-63) and human osteoblast cell line hFOB1 were used to detect the expressions of miRNA-218 and Runx2. When MG-63, 143B, Saos-2, and U2OS cells were compared to FOB1.19, MiRNA-218 expression was reduced in all four OS cell lines tested, with U2OS cells showing the greatest reduction ($P < 0.01$) (Fig. 1B). In terms of Runx2 expression, all four OS cell lines were significantly higher than FOB1.19 cells ($P < 0.05$). The accumulation of Runx2 expression was found to be highest in U2OS ($P < 0.01$) (Fig. 1C). As a result, U2OS cells were used for further investigation.

3.2. The role of miRNA-218 in the development and metastasis of U2OS cells

The miRNA-218 overexpression U2OS cells were generated by transfecting miRNA-218 mimics vector via Lipo3000 reagent (Invitrogen, USA) to assess the role of miRNA-218 in the development and metastasis of OS cells. The positive transfection was determined by RT-qPCR analysis. After transfection for 24 h, the expression of miRNA-218 in the U2OS cell line was remarkably increased in the miRNA-218 mimic group compared to the control groups ($P < 0.01$). MiRNA-218 expression in miRNA-218-ctrl group was comparable to the blank control group ($P > 0.05$) (Fig. 2A). MiRNA-218 overexpression obviously inhibited the cell proliferation at 48 h and 72 h of culture (Fig. 2B). The colony formation assay showed that miRNA-218 overexpressed U2OS cells displayed decreased colony formation ability compared to controls (Fig. 2C). To evaluate the antagonistic effects of miRNA-218 on metastasis of tumor cells, cell wound scratch and Transwell assays were conducted. As shown in Fig. 2D, the miRNA-218 overexpression obviously inhibited the
cell migration ability of U2OS cells, compared with miRNA-ctrl and blank control groups ($P < 0.01$). Meanwhile, the Transwell assay revealed that invaded cells were strikingly declined than that in the miRNA-218-ctrl and blank control groups ($P < 0.01$) (Fig. 2E and F). Similarly, miRNA-218 overexpression dramatically declined the number of migration cells compared with controls ($P < 0.01$) (Fig. 2E and G).

### 3.3. MiRNA-218 targets Runx2 interaction in OS development

MiRNA-218 was predicted to have a target binding site in the Runx2 3’UTR region between 1.3k and 1.4k using the TargetScan online tool (Fig. 3A). Western blot analysis was used to determine the target interaction between miRNA-218 and Runx2 following transfection with miRNA-218 mimics or a miRNA inhibitor. The results indicated that Runx2 protein levels were significantly increased in miRNA-218 mimic transfected U2OS cells, but significantly decreased following miRNA-218 silencing by siRNA (Fig. 3B). The luciferase assay also revealed a negative relationship between miRNA-218 and Runx2 expression. The luciferase activity of the wide-type 3’UTR of Runx2 was significantly reduced in U2OS cells co-transfected with miRNA-218 mimics, compared to the mutant 3’UTR of Runx2. There were no significant changes in luciferase activity in miRNA-218 mimics + mutant 3’-UTR, miRNA-Ctrl + wide-type 3’-UTR, and miRNA-Ctrl + mutant 3’-UTR sequence of Runx2 groups ($P > 0.05$, Fig. 3C).

### 3.4. MiRNA-218 attenuates U2OS cell proliferation and metastasis by targeting Runx2

To evaluate whether miRNA-218 functions via Runx2, U2OS cells were randomly divided into four groups, including miRNA-218 mimic + vector group, miRNA-218 mimic + Runx2 overexpression group, miRNA-218 ctrl + vector group, and miRNA-218 ctrl + Runx2 overexpression group. As expected, the protein expression of Runx2 was significantly lower in the miRNA-218 mimic + vector group, while it was reversed in the miRNA-218 mimic + Runx2 overexpression group (Fig. 4A). As determined by the CCK8 assay, the cell viability in miRNA-218 mimic transfected U2OS cells was the lowest among groups, while the miRNA-218-c in OE-Runx2 group was the highest. No significant difference was detected in the cell viability of miRNA-218-c + vector and miRNA-218-m + OE-Runx2 group (Fig. 4B). Similar results were obtained in the colony formation assay. The number of clones was lowest in miRNA-218 mimics transfected cells but significantly increased in the miRNA-218 mimics + OE-Runx2 group. Most clones were found in the miRNA-218-c + OE-Runx2 group. The ability of U2OS cells to form colonies in the miRNA-218 mimics + OE-Runx2 group was comparable to that of the miRNA-218-c group (Fig. 4C).

The cell wound scratch assay, and Transwell analysis were used to investigate the effect of miRNA-218 on the metastasis ability of U2OS cells by targeting Runx2. The reconstituted U2OS cells with miRNA-218 mimics showed markedly elevated migration ability than those treated with miRNA-218 mimics + OE-Runx2. The migration ability of cells in miRNA-218-c + OE-Runx2 group was highest among groups (Fig. 4D). In the Transwell assay, the number of migrating and invasive cells were significantly higher in miRNA-218-c + OE-Runx2 group, compared with miRNA-218 mimics + OE-Runx2 and miRNA-218-c + vector group ($P < 0.01$); while there was no obvious difference between miRNA-218 mimics + OE-Runx2 and miRNA-218-c + vector groups ($P > 0.05$) (Fig. 4E, F and G).

![Fig. 4. The inhibitive effect of miRNA-218 on cell proliferation, invasion and migration by targeting Runx2.](image)
4. Discussion

OS is a common type of bone cancer that originates in bone-forming mesenchymal cells. It is distinguished by rapid bone growth and a proclivity for metastasis [22]. Despite advances in therapeutic management, high-grade OS has a poor prognosis. OS treatment remains a challenge. Numerous studies have established that miRNAs play critical roles in the progression and development of OS [23,24]. MiRNA-199a-3p, a tumor suppressor gene, has been implicated in the growth and metastasis of OS cells [25]. MicroRNA-154-5p is not abundant in OS tissues, but its overexpression significantly inhibits OS tumorigenesis [26]. MiRNA-542-5p facilitated OS tumorigenesis by increasing cell proliferation and was proposed as a prognostic biomarker [27]. All of the preceding evidence points to miRNAs playing a critical role in the development and progression of OS.

miRNA-218, a tumor suppressor, is found to be significantly down-regulated in several cancers, including pancreatic cancer [28], cervical carcinoma [29], and thyroid cancer [30]. Numerous previous studies have established that miRNA-218 regulates target genes and thus plays a role in tumorigenesis [31–33]. MiRNA-218 expression was found to be significantly decreased in the serum of laryngeal cancer patients and was reported to be negatively correlated with the prognosis of laryngeal cancer patients [34]. MiRNA-218 increased the chemosensitivity and apoptosis in cervical cancer cells by suppressing surviving expression [35]. In addition, miRNA-218 inhibits the proliferation and metastasis of OS cells by mediating TIA1M1, MMP2, MMP9, and E2F2 expression and function [36,37]. However, the mechanism by which miRNA-218 contributes to OS is not entirely understood. In our study, miRNA-218 expression was significantly down-regulated in OS tumor tissues and cell lines, which was consistent with previous findings [37]. Furthermore, increasing miRNA-218 expression significantly reduced cell development and metastasis as measured by CCK8, colony formation, cell wound scratch, and Transwell assays, indicating that miRNA-218 plays a tumorsuppressive role in OS.

Runx2 is the first transcription factor detected in preosteoblasts and plays an essential role in different stages of osteogenesis through canonical Wnt signaling pathways [38]. The abnormal expression of Runx2 has been found in various tumor cells, which has been linked to tumor cell migration and oncogenesis [39]. Runx2 was recently identified as a direct target of miRNA-218, and its overexpression abolished the suppressive activity of miRNA-218 in ovarian cancer cell growth and metastasis [19]. The role of miRNA-218 by interaction with Runx2 has not been elucidated in OS genesis. Therefore, we investigated the role of miRNA-218 and Runx2 in OS oncogenesis in this study. In the present study, using the publicly available TargetScan online tool, we discovered that Runx2 is the direct target of miRNA-218. Furthermore, Runx2 was found to be significantly overexpressed in U2OS cells, while miRNA-218 expression was found to be the weakest in U2OS cells. The oncogenesis-related Runx2 gene was suppressed considerably by miRNA-218 overexpression, which was accompanied by clearly inhibited U2OS cell proliferation, migration, and invasion.

5. Conclusion

Overexpression of miRNA-218 inhibited the development and metastasis of OS, in part by regulating Runx2. Our study shed new light on miRNA-218’s role in inhibiting OS tumorigenesis, and we believe miRNA-218 can be a new prognostic marker and therapeutic target in OS.

Ethical approval

The study was carried out in accordance with the Helsinki Declaration and was approved by the Ethics Committee of Huaian Second People’s Hospital (approval No. JSHA2012-077-T).

Consent to participate

The written informed consent was obtained from all involved subjects.

Availability of data and material

The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

Consent to publish statement

N/A.

Funding

The authors declare that there are no sources of funding to be acknowledged.

Author contributions

Qiang Guo investigated, data analysis and wrote the draft-manuscript; Junan Ma participated in data analysis; Jing Wu designed and modified the manuscript. All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Declaration of competing interest

The authors declare no conflict of interest.

Acknowledgment

None.

References

[1] Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 2014;40(4):523–32. https://doi.org/10.1016/j.ctvr.2013.11.006.
[2] Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009;152:3–13. https://doi.org/10.1007/978-1-4419-0284-9_1.
[3] Kussuda Y, Miyake H, Geave ME, Fujisawa M. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model. Br J Cancer 2012;106(12):1945–52. https://doi.org/10.1038/bjc.2012.209.
[4] Mirabello L, Trousi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125(1):229–34. https://doi.org/10.1002/ijc.23420.
[5] Han X, Wang W, He J, Jiang L, Li X. Osteopontin as a biomarker for osteosarcoma therapy and prognosis. Oncol Lett 2019;17(3):2992–8.
[6] Lin Y, Jewell BE, Gingold J, Lu L, Zhao R, Wang LL, et al. Osteosarcoma: molecular pathogenesis and iPSC modeling. Trends Mol Med 2017;23(8): 737–55. https://doi.org/10.1016/j.molmed.2017.06.004.
[7] Hansen MF, Koudos A, Galef BL, Phillips RA, Podstad O, Brogger A, et al. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci U S A 1985;82(18):6216–20. https://doi.org/10.1073/pnas.82.18.6216.
[8] Ren D, Wei F, Hu L, Yang S, Wang C, Yuan X. Phosphorylation of Runx2, induced by cyclic mechanical tension via ERK1/2 pathway, contributes to osteodifferentiation of human periodontal ligament fibroblasts. J Cell Physiol 2015;230(10):2426–36. https://doi.org/10.1002/jcp.24972.
Siedlecki J, Wertheimer C, Wolf A, Liegl R, Priglinger C, Priglinger S, et al. Xie J, Yu F, Li D, Zhu X, Zhang X, Lv Z. MicroRNA-218 regulates cisplatin resistance. J Cell Physiol 2009;224(4):1531–8. https://doi.org/10.1002/jcp.22418.

Del Mare S, Aqelian RL. Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function. Sci Rep 2015;5(1):1–9. https://doi.org/10.1038/srep12959.

Maire G, Martin JW, Yoshimoto M, Chilton-MacNeill S, Zielenska M, Squire JA. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Canc Genet 2011;204(3):138–46. https://doi.org/10.1016/j.cancergen.2011.12.012.

Andersen GB, Knudsen A, Hager H, Hansen LL, Tost J. miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts. Mol Oncol 2018;12(1):114–31. https://doi.org/10.1016/j.molonc.2018.02.015.

He X, Dong Y, Wu CW, Liu X, Zhang W, Chen L, You G, Bao Z, et al. MicroRNA-218 inhibits the invasive ability of glioma cells by direct downregulation of IKB-ß. Tumor Biol 2016;37(1):1197–204. https://doi.org/10.1007/s13277-015-3831-2.

Li Y, Yan W, Zhang W, Chen L, You G, Bao Z, et al. MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncol Rep 2012;28(3):1013–21. https://doi.org/10.3892/or.2012.1962.

Kunoshita T, Hanazawa T, Nohata N, Kikkawa N, Enokida H, Yoshino H, et al. Tumor suppressive microRNA-218 inhibits cancer cell migration and invasion through targeting laminin-332 in head and neck squamous cell carcinoma. Oncotarget 2012;3(11):1386–400. https://doi.org/10.18632/oncotarget.709.

Guo J, Zeng X, Miao J, Liu J, Wei F, Liu D, et al. Expression of Concern: MiRNA-218 regulates osteoclast differentiation and inflammation response in periodontitis rats through Mmp9. Cell Microbiol 2019;21(4):e12979. https://doi.org/10.1111/cmi.12979.

Li N, Wang L, Tan G, Guo Z, Liu L, Yang WL. Reduced miRNA-218 expression in pancreatic cancer cell lines. J Cell Physiol 2013;228(4):714–23. https://doi.org/10.1002/jcp.24218.

Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H, et al. MicroRNA-199a-3p and its host gene SLIT3 cooperate to promote invasion and progression of thyroid cancer. J Clin Endocrinol Metab 2013;98(8):E1334–44. https://doi.org/10.1210/jc.2013-1053.

Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glomia cells by direct downregulation of IKB-ß. Biochem Biophys Res Commun 2010;402(1):135–40. https://doi.org/10.1016/j.bbrc.2010.10.003.

Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y, et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-aB activity. Neuro Oncol 2015;17(4):413–22. https://doi.org/10.1093/neuonc/nox296.

Zhang J, Sun C, Yu S, Wang Q, An T, Li Y, et al. Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis. Zhong Hua Bing Li Xue Za Zhi-Chinese journal of pathology 2011;40(7):454–9.

Guo L, Cai X, Hu W, Hua W, Yan W, Lin Y, et al. Expression and clinical significance of miRNA-145 and miRNA-218 in laryngeal cancer. Oncol Lett 2019;18(1):764–70. https://doi.org/10.3892/ol.2019.10533.

Yu M, Xu B, Yang H, Xue S, Zhang R, Zhang H, et al. MicroRNA-218 regulates the chemosensitivity of cervical cancer cells through targeting survivin. Cancer Manag Res 2019;11:6511–9. https://doi.org/10.2147/CMAR.S199650.

Xuan C, Jin M, Gao Y, Xu S, Wang L, Wang Y, et al. miR-218 suppresses the proliferation of osteosarcoma through downregulation of E2F2. Oncol Lett 2019;17(1):571–7. https://doi.org/10.3892/ol.2018.9576.

Jin J, Cai L, Liu Z-M, Zhou X-S, miRNA-218 inhibits osteosarcoma cell migration and invasion by down-regulating of TIM1, MMP2 and MMP9. Asian Pac J Cancer Prev 2013;14(6):3681–4. https://doi.org/10.7314/ APJCP.2013.14.6.3681.

Gaur T, Lengner CJ, Hovhannisyan H, Bhat RA, Bodine PV, Komm BS, et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression. J Biol Chem 2005;280(39):33132–40. https://doi.org/10.1074/jbc.M500608200.

Pratap J, Lian JB, Javed A, Barnes GL, Van WAJ, Stein JL, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006;25(4):589–600. https://doi.org/10.1007/s10555-006-9032-0.